Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

BACKGROUND: Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. Post-hoc integrated analyses evaluated the efficacy of lasmiditan in patients who reported a...

Descripción completa

Detalles Bibliográficos
Autores principales: Knievel, Kerry, Buchanan, Andrew S, Lombard, Louise, Baygani, Simin, Raskin, Joel, Krege, John H, Loo, Li Shen, Komori, Mika, Tobin, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950889/
https://www.ncbi.nlm.nih.gov/pubmed/31744319
http://dx.doi.org/10.1177/0333102419889350

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950889/
https://www.ncbi.nlm.nih.gov/pubmed/31744319
http://dx.doi.org/10.1177/0333102419889350

Ejemplares similares